Source Natural Foods & Herbal

BSE: SOURCENTRL · Pharmaceuticals · sector

₹113.85BSE close 2026-10-26

Key numbers

Market cap₹73 cr

Price₹113.85

52w high / low₹165 / ₹97

P/E19.9xSector median 27.9x

P/B2.9xSector median 2.9x

Book value₹40.0

Dividend yield–Sector median 0.48%

ROE15.4%Sector median 11.7%

ROCE17.1%Sector median 12.3%

OPM7.8%Sector median 14.0%

Debt / equity0.30xSector median 0.16x

EV/EBITDA12.6xSector median 18.6x

Interest cover7.6x

Current ratio2.18x

Sales growth 3y+52.6%Sector median +9.6%

Profit growth 3y+19.8%Sector median +13.3%

PEG1.02x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹2 cr vs borrowings ₹8 cr (FY26): borrowings are higher by ₹6 cr.
Operating profit covered interest 7.6x in the last 12 months.
Other income was 6% of net profit in the last 12 months.
No dividend in the last 5 financial years.
Price ₹113.85 on 2026-10-26: -31.0% from the 52-week high, +17.9% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹249.05 · low ₹105.10

Quarterly results

₹ cr	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	16	12	17	20	21	21
EBITDA	1	1	1	2	2	1
OPM %	7.6%	10.4%	8.0%	7.5%	10.7%	5.2%
Other income	0	0	0	0	0	0
Net profit	1	1	1	1	1	1
EPS (₹)	0.97	0.98	1.09	1.28	2.29	1.06
Revenue YoY					+30.9%	+76.4%
Profit YoY					+136.5%	+7.9%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	22	20	27	45	70	80
EBITDA	4	3	4	5	6	6
Net profit	2	2	2	3	4	4
EPS (₹)	3.78	3.30	2.70	4.51	5.64	5.72
Revenue growth		-8.1%	+37.9%	+64.5%	+56.7%	–
Profit growth		-12.8%	-17.9%	+66.7%	+25.9%	–
Dividend / share (₹)	–	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	+52.6%	–	–
Net profit	+19.8%	–	–
EPS	+19.6%	–	–
Share price	–	-32.9% (2y)	-26.6%

Balance sheet

₹ cr	FY25	FY26
Shareholders' equity	22	26
Borrowings	7	8
Cash & equivalents	7	2
Total assets	37	41
Fixed assets	4	4
Capital work in progress	0	0
Investments	0	0
Receivables	14	18
Inventory	6	8
Payables	3	5

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY25	FY26
Cash from operations	0	-2
Cash from investing	-5	-2
Cash from financing	5	-0
Capex	0	1
Free cash flow	-0	-3

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY25	FY26
ROE %	13.0%	14.2%
ROCE %	14.1%	16.6%
Debtor days	112	93
Inventory days	66	56
Payable days	36	36
Cash conversion cycle (days)	142	113
Working capital days	108	89

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
SOURCENTRL	₹73 cr	19.9x	2.9x	15.4%	17.1%	7.8%	+52.6%	–

All 185 companies in Pharmaceuticals →

Business segments (2026-06-30)

Segment	Revenue	Share	EBIT	Margin
Ayurveda	₹15 cr	64.6%	₹1 cr	5.5%
Energy	₹8 cr	35.4%	₹0 cr	5.8%

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	SOURCENTRL
BSE code	531398
ISIN	INE679C01027
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.